| P50 | author | Hiroshi Mitsumoto | Q90084178 |
| | Michael C. Graves | Q110725751 |
| | Leo McCluskey | Q115277346 |
| P2093 | author name string | David Saperstein | |
| | Robert G Miller | |
| | Alan Pestronk | |
| | Tahseen Mozaffar | |
| | Todd Levine | |
| | Howard Andrews | |
| | Richard J Barohn | |
| | Bruce Levin | |
| | Richard Bedlack | |
| | Kevin Boylan | |
| | Eric J Sorenson | |
| | Ying-Kuen Cheung | |
| | Elizabeth A Kelvin | |
| | Julie Rowin | |
| | Paul H Gordon | |
| | Julaine Florence | |
| | Jacqueline Montes | |
| | Rup Tandan | |
| | Michael Rivner | |
| | John Chapin | |
| | Robert B Macarthur | |
| | Stephen N Scelsa | |
| | Jau-Shin Lou | |
| | Carolyn Doorish | |
| | Kate Bednarz | |
| | Combination Drug Selection Trial Study Group | |
| | Jerry M Belsh | |
| P2860 | cites work | Phase II/III randomized trial of TCH346 in patients with ALS | Q28241484 |
| | Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation | Q29547561 |
| | El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis | Q29619074 |
| | Amyotrophic lateral sclerosis | Q29619516 |
| | Cyclooxygenase-2 inhibition prevents delayed death of CA1 hippocampal neurons following global ischemia | Q33566349 |
| | Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials | Q34327603 |
| | Mitochondrial involvement in amyotrophic lateral sclerosis | Q34535144 |
| | Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. | Q34584573 |
| | The role of creatine in the management of amyotrophic lateral sclerosis and other neurodegenerative disorders | Q35976264 |
| | Selecting promising ALS therapies in clinical trials. | Q36666006 |
| | Clinical pharmacokinetics of doxycycline and minocycline | Q39571569 |
| | A clinical trial of creatine in ALS. | Q40469445 |
| | Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. | Q43441867 |
| | Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis | Q43569621 |
| | Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice | Q43977943 |
| | Minocycline delays disease onset and mortality in a transgenic model of ALS. | Q44024931 |
| | Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis | Q44149270 |
| | Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS. | Q44226809 |
| | Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS. | Q44296123 |
| | A randomized sequential trial of creatine in amyotrophic lateral sclerosis | Q44383439 |
| | A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis | Q44562245 |
| | Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis | Q44726519 |
| | Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis | Q45291121 |
| | Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG. | Q45299923 |
| | A pilot, double-blind, placebo-controlled trial of indinavir in patients with ALS. | Q46433161 |
| | The ALSFRSr predicts survival time in an ALS clinic population | Q47867763 |
| | Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS. | Q47951637 |
| | Performance of the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) in multicenter clinical trials | Q48570656 |
| | Outcome measures for early phase clinical trials. | Q51906117 |
| | The utility of futility. | Q53274861 |
| | The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). | Q53535985 |
| | Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. | Q55032889 |
| | Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. | Q55041563 |
| | The Timed Up and Go test: Predicting falls in ALS | Q58251470 |
| | The Amyotrophic Lateral Sclerosis Functional Rating Scale. Assessment of activities of daily living in patients with amyotrophic lateral sclerosis. The ALS CNTF treatment study (ACTS) phase I-II Study Group | Q71098129 |
| | Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II | Q71177245 |
| | Quality of life in ALS is maintained as physical function declines | Q73550691 |
| | Recruitment of the mitochondrial-dependent apoptotic pathway in amyotrophic lateral sclerosis | Q74411605 |
| | A controlled trial of recombinant methionyl human BDNF in ALS: The BDNF Study Group (Phase III) | Q77398255 |
| | Differential expression of inflammation- and apoptosis-related genes in spinal cords of a mutant SOD1 transgenic mouse model of familial amyotrophic lateral sclerosis | Q77505248 |
| | Trial of celecoxib in amyotrophic lateral sclerosis | Q79794799 |
| P433 | issue | 4 | |
| P921 | main subject | amyotrophic lateral sclerosis | Q206901 |
| P304 | page(s) | 212-222 | |
| P577 | publication date | 2008-08-01 | |
| P1433 | published in | Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders | Q15759048 |
| P1476 | title | A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS. | |
| P478 | volume | 9 | |